Hookipa Pharma (NASDAQ:HOOK) Price Target Lowered to $5.00 at HC Wainwright

Hookipa Pharma (NASDAQ:HOOK) had its price target reduced by HC Wainwright from $6.50 to $5.00 in a report published on Friday, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Hookipa Pharma’s Q1 2025 earnings at ($0.17) EPS, Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.19) EPS and Q4 2025 earnings at ($0.19) EPS.

Separately, Royal Bank of Canada reaffirmed an outperform rating and set a $5.00 target price on shares of Hookipa Pharma in a report on Monday, March 25th.

Hookipa Pharma Trading Up 10.8 %

Shares of NASDAQ:HOOK opened at $0.89 on Friday. The firm’s fifty day moving average is $0.75 and its 200-day moving average is $0.66. Hookipa Pharma has a 52 week low of $0.41 and a 52 week high of $2.05.

Hookipa Pharma (NASDAQ:HOOK) last announced its quarterly earnings results on Friday, March 22nd. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.09. The company had revenue of $7.41 million for the quarter, compared to analysts’ expectations of $3.60 million. Hookipa Pharma had a negative net margin of 405.28% and a negative return on equity of 72.30%. As a group, equities analysts expect that Hookipa Pharma will post -0.51 earnings per share for the current fiscal year.

Hookipa Pharma Company Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.